Welcome to our dedicated page for Option Care Health news (Ticker: OPCH), a resource for investors and traders seeking the latest updates and insights on Option Care Health stock.
News about Option Care Health, Inc. (OPCH) centers on its role as the nation’s largest independent provider of home and alternate site infusion services and on its regular financial and corporate updates. The company issues detailed quarterly earnings releases, often accompanied by Form 8-K filings, that cover net revenue, net income, earnings per share, and non-GAAP metrics such as Adjusted EBITDA, Adjusted net income and Adjusted diluted EPS.
Investors following OPCH news will see announcements of preliminary and final quarterly and full-year financial results, as well as updated financial guidance ranges for net revenue, Adjusted EBITDA and Adjusted diluted earnings per share. These releases typically include management commentary on performance, cash flow from operations, stock repurchase activity and capital structure developments.
Option Care Health also uses news releases to communicate capital allocation decisions, such as expansions of its share repurchase program authorization, and to describe amendments to its credit agreements that affect term loans and revolving credit facilities. SEC Form 8-K filings referenced in the news provide additional detail on these material definitive agreements and financial obligations.
Corporate governance and leadership changes are another recurring news theme. For example, the company has announced a Chief Financial Officer transition, outlining the incoming CFO’s background, compensation arrangements and the outgoing CFO’s advisory role. News items also highlight Option Care Health’s participation in major healthcare and finance conferences, including events hosted by J.P. Morgan, UBS, Jefferies, Deutsche Bank and Bank of America, with webcasts and presentation materials made available to investors.
In addition, Option Care Health appears in partner company releases, such as Quince Therapeutics’ announcements of a strategic relationship for specialty infusion therapy support. These items describe how Option Care Health’s national network of specialty pharmacies and ambulatory infusion suites may be used to administer specific infused therapies, particularly in rare disease indications. For ongoing coverage of these financial, strategic and operational developments, OPCH news on this page aggregates company press releases, partner announcements and related disclosures.
Option Care Health announced a proposed underwritten offering of $350 million in common stock, involving $125 million from the Company and $225 million from Madison Dearborn Partners. Additionally, a 30-day option for underwriters to purchase up to $52.5 million is planned. The net proceeds will primarily be used to pay down senior secured second lien floating rate notes due 2027. BofA Securities leads the offering, with several other significant banks acting as bookrunners. A shelf registration statement has been filed with the SEC.
Option Care Health (Nasdaq: OPCH) announced preliminary financial results for Q2 2020, reporting a net revenue of approximately $740.8 million, a 7% increase year-over-year. However, the company incurred a net loss of $7.7 million. Adjusted EBITDA was around $54.6 million, representing 7.4% of revenue. Despite challenges from the COVID-19 pandemic, there was notable growth in chronic revenue. The company reinstated its full-year guidance, expecting $200-$210 million in Adjusted EBITDA and at least $50 million in Free Cash Flow.
Option Care Health, the largest independent provider of home and alternate site infusion services in the U.S., announced they will present at the William Blair Virtual Growth Stock Conference on June 11, 2020. CEO John Rademacher and CFO Mike Shapiro are set to speak at 8:00 a.m. CDT. A live audio webcast of the presentation will be available, along with a replay, on their investor relations website. Option Care Health employs over 5,000 teammates, including approximately 2,900 clinicians, dedicated to enhancing patient care across all 50 states.
Option Care Health (NASDAQ: OPCH) has been chosen by UroGen Pharma (NASDAQ: URGN) as a preferred national pharmacy provider for the delivery of Jelmyto™, a new cancer treatment for low-grade upper tract urothelial cancer. This first-in-class treatment combines mitomycin with a hydrogel technology for effective tumor targeting. Approved by the FDA on April 15, 2020, Jelmyto requires specialized preparation and delivery, which Option Care Health’s nationwide network of USP 800 pharmacies can provide, ensuring safety and compliance. This partnership enhances patient access to innovative therapies.
Option Care Health (Nasdaq: OPCH) reported strong financial results for Q1 2020, highlighting net revenue of $705.4 million, a 48% increase from Q1 2019. Gross profit rose to $158.0 million, representing 22.4% of net revenue. Despite a net loss of $19.9 million ($0.11 per share), the company achieved an adjusted EBITDA of $40.2 million, up 107.6%. Cash flow from operations reached $18.4 million, up 102.7%. The company has maintained cash balances of $77.2 million with no borrowings on its revolver. Future impacts of COVID-19 on referrals and costs remain uncertain.
Summary not available.